The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary ArteroDivision of Nephrology and Division of Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyAbstract: Basiliximab is a chimeric mouse-human monoclonal antibo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary Artero
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/19c5284fbc23402b90ca3fa69495bc19
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19c5284fbc23402b90ca3fa69495bc19
record_format	dspace
spelling	oai:doaj.org-article:19c5284fbc23402b90ca3fa69495bc192021-12-02T03:48:20ZThe role of basiliximab in the evolving renal transplantation immunosuppression protocol1177-54751177-5491https://doaj.org/article/19c5284fbc23402b90ca3fa69495bc192008-06-01T00:00:00Zhttp://www.dovepress.com/the-role-of-basiliximab-in-the-evolving-renal-transplantation-immunosu-a1724https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary ArteroDivision of Nephrology and Division of Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyAbstract: Basiliximab is a chimeric mouse-human monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor on activated T lymphocytes. It was shown in phase III trials to reduce the number and severity of acute rejection episodes in the first year following renal transplantation in adults and children, with a reasonable cost-benefit ratio. The drug does not increase the incidence of opportunistic infections or malignancies above baseline in patients treated with conventional calcineurin inhibitor-based immunosuppression. In the field of renal transplantation, basiliximab does not increase kidney or patient survival, despite the reduction in the number of rejection episodes. Basiliximab may reduce the incidence of delayed graft function. In comparison with lymphocyte-depleting antibodies basiliximab appears to have equal efficacy in standard immunological risk patients. Recently, IL-2 receptor monoclonal antibodies have been used with the objective of reducing or eliminating the more toxic elements of the standard immunosuppression protocol. Several trials have incorporated basiliximab in protocols designed to avoid or withdraw rapidly corticosteroids, as well as protocols which substitute target-of-rapamycin (TOR) inhibitors for calcineurin inhibitors.Keywords: basiliximab, renal transplantation, IL-2 receptor antagonists, induction, immunosuppression, corticosteroids, calcineurin inhibitors Paola SalisChiara CaccamoRoberto VerzaroSalvatore GruttadauriaMary ArteroDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 175-188 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Paola Salis Chiara Caccamo Roberto Verzaro Salvatore Gruttadauria Mary Artero The role of basiliximab in the evolving renal transplantation immunosuppression protocol
description	Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary ArteroDivision of Nephrology and Division of Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyAbstract: Basiliximab is a chimeric mouse-human monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor on activated T lymphocytes. It was shown in phase III trials to reduce the number and severity of acute rejection episodes in the first year following renal transplantation in adults and children, with a reasonable cost-benefit ratio. The drug does not increase the incidence of opportunistic infections or malignancies above baseline in patients treated with conventional calcineurin inhibitor-based immunosuppression. In the field of renal transplantation, basiliximab does not increase kidney or patient survival, despite the reduction in the number of rejection episodes. Basiliximab may reduce the incidence of delayed graft function. In comparison with lymphocyte-depleting antibodies basiliximab appears to have equal efficacy in standard immunological risk patients. Recently, IL-2 receptor monoclonal antibodies have been used with the objective of reducing or eliminating the more toxic elements of the standard immunosuppression protocol. Several trials have incorporated basiliximab in protocols designed to avoid or withdraw rapidly corticosteroids, as well as protocols which substitute target-of-rapamycin (TOR) inhibitors for calcineurin inhibitors.Keywords: basiliximab, renal transplantation, IL-2 receptor antagonists, induction, immunosuppression, corticosteroids, calcineurin inhibitors
format	article
author	Paola Salis Chiara Caccamo Roberto Verzaro Salvatore Gruttadauria Mary Artero
author_facet	Paola Salis Chiara Caccamo Roberto Verzaro Salvatore Gruttadauria Mary Artero
author_sort	Paola Salis
title	The role of basiliximab in the evolving renal transplantation immunosuppression protocol
title_short	The role of basiliximab in the evolving renal transplantation immunosuppression protocol
title_full	The role of basiliximab in the evolving renal transplantation immunosuppression protocol
title_fullStr	The role of basiliximab in the evolving renal transplantation immunosuppression protocol
title_full_unstemmed	The role of basiliximab in the evolving renal transplantation immunosuppression protocol
title_sort	role of basiliximab in the evolving renal transplantation immunosuppression protocol
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/19c5284fbc23402b90ca3fa69495bc19
work_keys_str_mv	AT paolasalis theroleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT chiaracaccamo theroleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT robertoverzaro theroleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT salvatoregruttadauria theroleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT maryartero theroleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT paolasalis roleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT chiaracaccamo roleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT robertoverzaro roleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT salvatoregruttadauria roleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol AT maryartero roleofbasiliximabintheevolvingrenaltransplantationimmunosuppressionprotocol
_version_	1718401593928318976

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Ejemplares similares